Rehabilitation Robotic System ReHand
Robotic-Assisted Upper Limb Rehabilitation After Stroke Using the ReHand System: A Randomized Controlled Trial
1 other identifier
interventional
120
1 country
1
Brief Summary
The aim of this clinical trial is to investigate the efficacy of the ReHand rehabilitation system for the recovery of patients after a stroke. The main objectives of the study:
- 1.To assess the functional state of patients with cerebral stroke according to the The Barthel Index, on the Functional Independence Measure (FIM) scale of functional independence.
- 2.To assess the neurological deficit of patients according to the National Institutes of Health Stroke Scale (NIHSS), the state of function of the affected arm and the degree of fine motor impairment according to the The Frenchay Arm Test (FAT), The Fugl-Meyer Assessment for upper extremity (FMA-UE) scale, modified Wolf Motor Function Test (mWMFT), according to the upper limb disability questionnaire The Disabilities of the Arm, Shoulder, and Hand (DASH) test.
- 3.To investigate the state of psycho-emotional status in patients on the Hospital Anxiety and Depression Scale (HADS) of anxiety and depression.
- 4.To determine the effectiveness of the rehabilitation performed in patients with cerebral stroke after recovery by the ReHand system according to the above scales.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable stroke
Started Mar 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2024
CompletedFirst Submitted
Initial submission to the registry
March 29, 2025
CompletedFirst Posted
Study publicly available on registry
April 22, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2025
CompletedResults Posted
Study results publicly available
August 5, 2025
CompletedAugust 5, 2025
July 1, 2025
1.2 years
March 29, 2025
June 29, 2025
July 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
Fugl-Meyer Assessment for Upper Extremity (FMA-UE); range: 0-66 points; higher scores indicate better motor function and less impairment.
60 days later
Secondary Outcomes (7)
Barthel Index (BI)
60 days later
Functional Independence Measure Scale (FIM)
60 days later
National Institutes of Health Stroke Scale (NIHSS)
60 days later
Frenchay Arm Test
60 days later
Modified Wolf Motor Function Test (mWMFT)
60 days later
- +2 more secondary outcomes
Study Arms (2)
intervention group: Robot Rehand + Standard Rehabilitation
EXPERIMENTALThe patients in the main group will undergo standard rehabilitation combined with the use of the ReHand robotic device, five times per week for 60 days.
Control group: Standard Rehabilitation Only
ACTIVE COMPARATORPatients in the control group will undergo standard rehabilitation, without the use of the ReHand robotic device. They will attend sessions 5 times per week for 60 days.
Interventions
The exoskeleton hand system provides recovery and training for paralyzed fingers using an innovative method that mirrors the movements of a healthy hand. The system uses a sensor glove to read movements and transfer them to a rehabilitation glove. This forces the injured hand to repeat the same movements as the healthy hand, helping to restore motor skills. The system combines flexible robotics with neuroscience to help patients retrain their muscles. It reduces muscle tension and swelling, relieves stiffness, improves blood circulation, and restores muscle performance after atrophy. It also reduces hypertension and joint pain, and activates neuroplasticity through passive and active techniques. All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020.
All patients received standard rehabilitation treatments in accordance with clinical protocol No. 94 for the third stage of medical rehabilitation, approved by the Joint Commission on Quality of Medical Services from the Ministry of Health of Kazakhstan on 14 May 2020.
Eligibility Criteria
You may qualify if:
- a stroke that occurred no more than six months prior;
- absence of somatic conditions that would interfere with the use of the hand exoskeleton system (such as rheumatoid arthritis, severe muscle hypertonia, joint pathology, fractures, etc.);
- clear consciousness;
- presence of upper limb and fine motor impairments;
- no history of recurrent cerebral strokes;
- no comorbidities associated with cognitive dysfunction (such as Parkinson's disease, Wernicke's encephalopathy, alcoholic encephalopathy, etc.) that would hinder instruction comprehension;
- absence of rheumatological issues (including contractures and significant pain syndromes) that would impede study participation;
- absence of acute or chronic (in the decompensated stage) diseases of internal organs;
- signing of informed consent for study participation;
- all participants were adults
You may not qualify if:
- lack of clear consciousness,
- a history of recurrent cerebral stroke,
- a stroke that occurred more than 6 months ago,
- lack of upper limb function or fine motor disorders,
- the presence of concomitant diseases associated with cognitive dysfunction (such as Parkinson's disease, Wernicke encephalopathy, alcoholic encephalopathy, etc.) that may interfere with understanding the instructions,
- rheumatological diseases.
- problems (including contractures and severe pain syndromes) that could interfere with participation in the study,
- the presence of acute or chronic (decompensation stage) diseases of internal organs,
- contraindications according to Clinical Protocol No. 94 on diagnosis and treatment "The third stage of medical rehabilitation", approved by the Ministry of Health of the Republic of Kazakhstan on May 14, 2020 (frequent or severe bleeding of various origins; febrile or subfebrile fever of unknown origin; acute infectious diseases; acute osteomyelitis; acute deep vein thrombosis; complicated cardiac arrhythmias, heart failure in the active stage; active forms of tuberculosis; malignant tumors (IV clinical group).; respiratory failure of stage III and above; various purulent (pulmonary) diseases with significant intoxication; decompensated diseases such as irreversible metabolic disorders (diabetes mellitus, myxedema, thyrotoxicosis, etc.), functional insufficiency of the liver or pancreas of stage III; epilepsy in the seizure phase; mental disorders causing desocialization and emotional or behavioral disorders.; purulent skin diseases, infectious skin diseases (scabies, fungal infections, etc.); anemia with an Hb level of 90 g/l or lower;
- lack of signed informed consent to participate in the study.;
- he underage age of the participants.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Karaganda region
Karaganda, 100008, Kazakhstan
Related Publications (1)
Amirbekova M, Kispayeva T, Izbassarova A, Adomaviciene A, Sorokina M, Zhunussova T. Rehabilitation of patients in the subacute phase of stroke using the ReHand robotic system: a randomized controlled trial. Front Hum Neurosci. 2025 Nov 24;19:1690643. doi: 10.3389/fnhum.2025.1690643. eCollection 2025.
PMID: 41377192DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Amirbekova Mariyam Sayatovna
- Organization
- Karaganda Medical University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 29, 2025
First Posted
April 22, 2025
Study Start
March 1, 2024
Primary Completion
May 30, 2025
Study Completion
May 30, 2025
Last Updated
August 5, 2025
Results First Posted
August 5, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share